Neil Kumar - 17 Mar 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: BBIO
Reported as of: 17 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Mar 2026, 16:28:10 UTC
Prior SEC filing: 16 Mar 2026
Next SEC filing: 31 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Will Solis, Attorney-in-Fact

Key filing fact

Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 19 Mar 2026.

Key facts

This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 19 Mar 2026, 16:28.

Change

Previous filing in this sequence was filed on 16 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742485 Primary reporting owner

Kumar Neil

Relationship: Chief Executive Officer, Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Will Solis, Attorney-in-Fact
Signature date: 19 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +40,570
Change %
Price: $0.000000^*
Shares after: 40,570
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,570
Exercise price: $70.94
Footnotes: F1

BBIO transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +104,313
Change %
Price: $0.000000^*
Shares after: 104,313
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 104,313
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

1/16th of the shares subject to this option vest and become exercisable on May 16, 2026, and thereafter, 1/16th of the shares subject to this option will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.

Footnote F2

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F3

The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.